• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Limerick BioPharma

edit

Limerick BioPharma is dedicated to developing compounds that, when used adjunctively with both marketed and investigational drugs, significantly improve the quality of patients’ lives. Their compounds minimize toxic side effects at non-targeted vulnerable organs and tissue while maintaining or enhancing a drug’s desired effects. In the monotherapy setting, they are developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia.

Milestones

edit

• 
  Limerick BioPharma received $3.59M in Debt funding. (12/23/10)
  Posted 12/26/10 at 6:40pm via xconomy.com
• 
  Limerick BioPharma received $15M in Series C funding. (7/15/09)
  Posted 7/15/09 at 2:56pm via fiercebiotech.com
• 
  Limerick BioPharma received $15.2M in Unattributed funding. (6/11/08)
  Posted 6/26/09 at 11:32pm via venturebeat.com
• 
  Limerick BioPharma received $1.5M in Series A funding. (6/13/09)
  Posted 6/15/09 at 8:41am via venturebeat.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 6/14/09

Sources

1. Limerick BioPharma raises $15.2M for drug bioavailability (deals.venturebeat.com) [edit]
2. Limerick BioPharma raises $1.5M to limit drug side effects (deals.venturebeat.com) [edit]
3. Limerick lands $15M in Series C (fiercebiotech.com) [edit]
4. Limerick BioPharma Lands $3,585,000 New Funding Round (xconomy.com) [edit]